Synthesis of Butein Analogues and their Anti-proliferative Activity Against Gefitinib-resistant Non-small Cell Lung Cancer (NSCLC) through Hsp90 Inhibition
作者:Young Ho Seo、Ju Hui Jeong
DOI:10.5012/bkcs.2014.35.5.1294
日期:2014.5.20
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer representing 85% of lung cancer patients. Despite several EGFR-targeted drugs have been developed in the treatment of NSCLC, the clinical efficacy of these EGFR-targeted therapies is being challenged by the occurrence of drug resistance. In this regard, Hsp90 represents great promise as a therapeutic target of cancerous diseases due to its role in modulating and stabilizing numerous oncogenic proteins. Accordingly, inhibition of single Hsp90 protein simultaneously disables multiple signaling networks so as to overcome drug resistance in cancer. In this study, we synthesized a series of 11 butein analogues and evaluated their biological activities against gefitinibresistant NSCLC cells (H1975). Our study indicated that analogue 1h inhibited the proliferation of H1975 cells, down-regulated the expression of Hsp90 client proteins, including EGFR, Met, Her2, Akt and Cdk4, and upregulated the expression of Hsp70. The result suggested that compound 1h disrupted Hsp90 chaperoning function and could serve a potential lead compound to overcome the drug resistance in cancer chemotherapy.
非小细胞肺癌(NSCLC)是最常见的肺癌类型,占肺癌患者的85%。尽管针对NSCLC开发了几种EGFR靶向药物,但这些EGFR靶向治疗的临床疗效正受到药物耐药性的挑战。在此背景下,由于Hsp90在调节和稳定多种致癌蛋白中的作用,它作为癌症疾病的潜在治疗靶点展现了巨大希望。相应地,通过抑制单个Hsp90蛋白,可以同时阻断多个信号网络,从而克服癌症中的药物耐药性。在本研究中,我们合成了一系列11个白杨素类似物,并评估了它们对吉非替尼耐药的NSCLC细胞(H1975)的生物活性。我们的研究表明,类似物1h抑制了H1975细胞的增殖,下调了Hsp90客户端蛋白的表达,包括EGFR、Met、Her2、Akt和Cdk4,并上调了Hsp70的表达。这些结果表明,化合物1h破坏了Hsp90的伴侣功能,并可能作为一种潜在的先导化合物,用于克服癌症化疗中的药物耐药性。